That's it @LearningEachDay however you look at it, it is progress on the SR-aGVHD indication ..... like I have said previously, I did not invest in Mesoblast for Remestemcel-L / GVHD, I invested in Mesoblast for both the CHF and CLBP indications.....
..... while an approval for Remestemcel-L even if only in <12 yo's would open doors for the company through SR-aGVHD revenue and subsequently label extensions I am more interested in the feedback on CHF this coming quarter; that is what will be the company maker IMO and where I anticipate a large partnership will materialise
GLTAH
Ann: Submits New Information to FDA IND File for SR-aGVHD, page-269
-
- There are more pages in this discussion • 308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 94.0¢ | 89.5¢ | $4.970M | 5.436M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18877 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 6795 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |